癌症相关与非癌症相关脓毒症住院的流行病学与结局
该观察性队列利用2013—2014年美国全国再入院数据库(覆盖49%美国全支付方索赔)的1,104,363例脓毒症住院,按继发恶性肿瘤诊断码分为癌症相关与非癌症相关脓毒症。癌症相关脓毒症住院死亡率为27.9%,非癌症相关为19.5%;调整后住院死亡率绝对增加范围为2.2%至15.2%,差异在年轻成人中最大并随年龄增长而减弱。癌症相关脓毒症出院后30天内再住院率为23.2%,非癌症相关为20.1%(P < 0.001)。特定器官功能障碍发生率存在小幅度差异(如血液系统功能障碍20.1% vs 16.6%,P < 0.001),但器官功能障碍中位数无法区分。
要点
- 在1,104,363例脓毒症住院中,癌症相关脓毒症住院死亡率为27.9%,非癌症相关为19.5%。
- 癌症相关脓毒症调整后住院死亡率绝对增加范围为2.2%至15.2%,该差异在年轻成人中最大并随年龄增长而减弱。
- 癌症相关脓毒症出院后30天再住院率为23.2%,非癌症相关为20.1%(P < 0.001)。
- 癌症相关脓毒症中血液系统功能障碍发生率为20.1%,非癌症相关为16.6%(P < 0.001),但器官功能障碍中位数无法区分。
- 超过五分之一的脓毒症住院为癌症相关(1,104,363例脓毒症住院中癌症相关占五分之一以上)。
适用人群与场景
- 美国全国再入院数据库(2013—2014年)中1,104,363例脓毒症住院,覆盖49%美国全支付方索赔。
- 按继发恶性肿瘤诊断码分为癌症相关与非癌症相关脓毒症住院。
诊断标准与关键阈值
- 使用严重脓毒症、脓毒性休克明确编码或Dombrovskiy标准(感染与器官功能障碍伴随编码)识别脓毒症住院。
- 根据继发恶性肿瘤诊断码的存在将住院分类为癌症相关与非癌症相关脓毒症。
研究设计与关键结果
- 观察性队列研究,纳入1,104,363例脓毒症住院(占2013—2014年全国再入院数据库27,481,517例住院的4.0%),癌症相关住院为4,150,998例(15.1%)。
- 癌症相关脓毒症住院死亡率为27.9%,非癌症相关为19.5%。
- 癌症相关脓毒症调整后住院死亡率绝对增加范围为2.2%至15.2%,差异在年轻成人中最大并随年龄增长而减弱。
- 癌症相关脓毒症出院后30天再住院率为23.2%,非癌症相关为20.1%(P < 0.001)。
- 器官功能障碍中位数无法区分,但特定器官功能障碍发生率存在小幅度差异:血液系统功能障碍20.1% vs 16.6%(P < 0.001)。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Cancer and its treatment are known to be important risk factors for sepsis, contributing to an estimated 12% of U.S. sepsis admissions in the 1990s. However, cancer treatment has evolved markedly over the past 2 decades. We sought to examine how cancer-related sepsis differs from non-cancer-related sepsis.
DESIGN: Observational cohort.
SETTING: National Readmissions Database (2013-2014), containing all-payer claims for 49% of U.S.
PATIENTS: A total of 1,104,363 sepsis hospitalizations.
INTERVENTIONS: We identified sepsis hospitalizations in the U.S. National Readmissions Database using explicit codes for severe sepsis, septic shock, or Dombrovskiy criteria (concomitant codes for infection and organ dysfunction). We classified hospitalizations as cancer-related versus non-cancer-related sepsis based on the presence of secondary diagnosis codes for malignancy. We compared characteristics (site of infection and organ dysfunction) and outcomes (in-hospital mortality and 30-d readmissions) of cancer-related versus non-cancer-related sepsis hospitalizations. We also completed subgroup analyses by age, cancer types, and specific cancer diagnoses.
MEASUREMENTS AND MAIN RESULTS: There were 27,481,517 hospitalizations in National Readmissions Database 2013-2014, of which 1,104,363 (4.0%) were for sepsis and 4,150,998 (15.1%) were cancer related. In-hospital mortality in cancer-related sepsis was 27.9% versus 19.5% in non-cancer-related sepsis. The median count of organ dysfunctions was indistinguishable, but the rate of specific organ dysfunctions differed by small amounts (e.g., hematologic dysfunction 20.1% in cancer-related sepsis vs 16.6% in non-cancer-related sepsis; p < 0.001). Cancer-related sepsis was associated with an adjusted absolute increase in in-hospital mortality ranging from 2.2% to 15.2% compared with non-cancer-related sepsis. The mortality difference was greatest in younger adults and waned with age. Patients (23.2%) discharged from cancer-related sepsis were rehospitalized within 30 days, compared with 20.1% in non-cancer-related sepsis (p < 0.001).
CONCLUSIONS: In this cohort of over 1 million U.S. sepsis hospitalizations, more than one in five were cancer related. The difference in mortality varies substantially across age spectrum and is greatest in younger adults. Readmissions were more common after cancer-related sepsis.
参考来源
- Hensley MK, Donnelly JP, Carlton EF, et al. Epidemiology and Outcomes of Cancer-Related Versus Non-Cancer-Related Sepsis Hospitalizations. Crit Care Med. 2019. PMID: 31356477. doi:10.1097/CCM.0000000000003896
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。